IRINVAC

IMMUNE RESPONSES TO INFLUENZA VACCINE

 Coordinatore FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA 

 Organization address address: Via Vincenzo Vela 6
city: BELLINZONA
postcode: 6500

contact info
Titolo: Mr.
Nome: Gabriele
Cognome: Gendotti
Email: send email
Telefono: +41 918200309

 Nazionalità Coordinatore Switzerland [CH]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-CIG
 Funding Scheme MC-CIG
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-08-01   -   2017-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA

 Organization address address: Via Vincenzo Vela 6
city: BELLINZONA
postcode: 6500

contact info
Titolo: Mr.
Nome: Gabriele
Cognome: Gendotti
Email: send email
Telefono: +41 918200309

CH (BELLINZONA) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

global    cell    variants    vaccination    influenza    vaccines    health    techniques    transport    protective    virus   

 Obiettivo del progetto (Objective)

'Influenza virus continues to represent a major global health problem and the recent pandemic caused by a H1N1 strain of influenza A (swine flu) is a good example of its potential global threat to health. Vaccination again influenza confers in most of the cases protection against the disease, mainly due to a robust humoral response. However, yearly vaccinations are required in order to protect against new circulating variants of the virus. Another important limitation of the current influenza vaccines is the development of a suboptimal immunogenicity in the elderly, in patients with serious chronic diseases, in the immunocompromised, and in young children, which correlates with higher morbidity and mortality in these risk groups. In addition, the presence of adjuvants in the formulation of most of the vaccines has been questioned due to potential health risks associated with their toxicity. The general aim of this project is to understand the immunological events that lead to the establishment of a protective response against influenza virus in the lymph node after vaccination. To pursue that aim we will evaluate the capture and transport of the viral particles from the injection site to the B cell follicle where the antibody response is initiated. We will use a multidisciplinary approach to evaluate the main questions of the project including state-of-the-art imaging techniques, such as intravital-2photon microscopy to study cell interaction and antigen transport in vivo, molecular techniques such as microarray analysis to study specific transcriptome profiling after vaccination and microbiology techniques to develop new fluorescent variants of the virus. Understanding the mechanism of action of the influenza vaccine will enable the manipulation of the immune response to induce a stronger immunogenic, and a safer protective response through vaccination.'

Altri progetti dello stesso programma (FP7-PEOPLE)

NRFDIABVASC (2008)

"Role of Nrf2 transcription factor in diabetic vasculopathy, oxidative stress and inflammation."

Read More  

HIGGSEFT (2014)

Higgs precision era at the LHC

Read More  

DIFNONLOC (2012)

Diffusive Partial Differential Equations with Nonlocal Interaction in Biology and Social Sciences

Read More